John Hussman's SRPT Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 84,000 shares of Sarepta Therapeutics, Inc. (SRPT) worth $1.62 M, representing 0.35% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, John Hussman has maintained this position in SRPT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 52,500 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by John Hussman
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2025 | +10,500 | New Buy | 10,500 | $63.82 |
| Q2 2025 | +52,500 | Add 500.00% | 63,000 | $17.10 |
| Q3 2025 | +21,000 | Add 33.33% | 84,000 | $19.27 |
John Hussman's Sarepta Therapeutics Investment FAQs
John Hussman first purchased Sarepta Therapeutics, Inc. (SRPT) in Q1 2025, acquiring 10,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Sarepta Therapeutics, Inc. (SRPT) for 3 quarters since Q1 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q2 2025, adding 63,000 shares worth $1.08 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 84,000 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $1.62 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.35% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 84,000 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.